The European Medicines Agency has issued a positive opinion for Aimovig (erenumab), an antibody treatment for migraine prevention, only weeks after it was given approval by the US Food and Drug Administration. Both agencies highlighted the novelty of the drug which is the first preventive treatment for migraine.
It works by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.